The FDA approved Kapvay (clonidine hydrochloride extended -release) as a monotherapy and adjunctive therapy for the treatment of attention- deficit/hyperactivity disorder in children and adolescents aged 6 to 17 years.
Nicole Russo, PharmD Candidate
Advertisement
Articles by Nicole Russo, PharmD Candidate
Advertisement
Latest Updated Articles
- Shionogi Pharma's Kapvay
Published: March 14th 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk
2
Is Berberine Nature’s GLP-1?
3
Glucodensity Analysis Enhances CGM Accuracy for Detecting Cystic Fibrosis–Related Diabetes
4
Incidence of Invasive Fungal Infections Following BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma
5
